Revance CEO Mark J. Foley stated that the merger provides substantial value to shareholders while expanding the combined company’s product portfolio and provider network. The deal is subject to regulatory approvals and other conditions and is anticipated to close by the end of 2024.
This statement and the frequent very short term extensions to the tender date make me suspect that there will be a definitive result before the end of this month. … and it’s not likely to make the current shareholders very happy.